Information Provided By:
Fly News Breaks for June 19, 2019
MRTX
Jun 19, 2019 | 09:18 EDT
B. Riley FBR analyst Harshita Polishetty downgraded Mirati Therapeutics to Neutral from Buy while raising her price target for the shares to $92. The "de-risking" of MRTX849 is balanced by the 141% year-to-date rally in the shares, Polishetty tells investors in a research note. The analyst sees no significant share catalysts until 2020, which she believes increases "sell on the news" risk from the MRTX849 readout expected later this year.
News For MRTX From the Last 2 Days
There are no results for your query MRTX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.